The publisher explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (28 October 2020)
Model updates (29 October 2019)
Model updates (14 August 2019)
Snapshot
- Overview - Sumitomo Dainippon is projected to see growth until the loss of exclusivity for Latuda, while recent additions to the late-stage pipeline will offset some of the revenue declines.
- Key themes - [1] Sumitomo Dainippon’s topline revenues are affected primarily by Latuda, which is forecast to grow until 2023 and then see a significant decline due to its patent expiry [2] Strategic alliance with Roivant brings relugolix and vibegron into Sumitomo Dainippon’s portfolio.
Model updates (28 October 2020)
- Galvus forecast adjusted higher due to launch trend of Equa in Japan
- Trulicity forecast adjusted higher due to continued market share gains
- APL-130277 name changed to Kynmobi
- Relugolix forecast added
- Vibegron forecast added.
Model updates (29 October 2019)
- Alvocidib launch delayed
- APL-130277 launch delayed
- Napabucasin launch added.
Model updates (14 August 2019)
- Metgluco forecast adjusted higher due to company guidance
- Surepost forecast adjusted lower due to company guidance
- Trulicity forecast adjusted higher due to company guidance
- Lonasen forecast adjusted lower due to generic competition
- Latuda forecast adjusted lower due to company guidance
- Rethio forecast added
- Imeglimin forecast added.
Table of Contents
Company Background
Company Forecast
Company Profile
Clinical Trial Overview
